In summary, we reported that treatment with ghrelin specifically promoted cisplatin sensitivity by inducing phosphorylation of CDK1 at Tyr15 and Thr14 via inhibiting the phosphorylation of p38, and subsequently promoting S phase cell cycle arrest in the HO-8910 PM ovarian cancer cell line. Here, GHRL is linked to ovarian cancer.